Production (Stage)
Protalix BioTherapeutics, Inc.
PLX
$1.58
$0.063.95%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -44.49% | 1.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -44.49% | 1.44% | |||
| Cost of Revenue | 110.50% | -53.60% | |||
| Gross Profit | -86.51% | 49.54% | |||
| SG&A Expenses | -13.20% | 15.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.51% | -21.18% | |||
| Operating Income | -157.50% | 80.63% | |||
| Income Before Tax | -151.01% | 90.37% | |||
| Income Tax Expenses | -113.75% | 35.42% | |||
| Earnings from Continuing Operations | -155.73% | 100.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -155.73% | 100.68% | |||
| EBIT | -157.50% | 80.63% | |||
| EBITDA | -150.36% | 74.61% | |||
| EPS Basic | -151.03% | 110.23% | |||
| Normalized Basic EPS | -146.70% | 99.08% | |||
| EPS Diluted | -174.21% | 88.72% | |||
| Normalized Diluted EPS | -169.41% | 47.97% | |||
| Average Basic Shares Outstanding | 9.10% | -4.53% | |||
| Average Diluted Shares Outstanding | -26.56% | 28.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||